Background: The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer.
of extra-axillary lymph node involvement. In 15 patients (15%), extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 14% (14/103) and ultimately a modification of planned treatment in 8% (8/103) of patients.
Conclusions: PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative 18 F-fluorodeoxyglucose-PET/CT has a substantial impact on initial staging and on clinical management in patients with early-stage breast cancer with tumors ≥2 cm. Key words: breast cancer, initial staging, PET/CT, treatment modification introduction Accurate initial staging of patients with breast cancer is essential for precise prognostication and optimal choice of therapy. For initial assessment of primary breast cancer, mammography is still the most widely utilized modality usually complemented with ultrasound (US) for the evaluation of axillary nodal involvement. Combined positron emission tomography and computed tomography (PET/CT) is now increasingly available and has widely replaced PET as a clinical tool since PET/CT in several reports has demonstrated diagnostic superiority compared with PET alone [1] [2] [3] .
With the radioactive tracer 18 F-fluorodeoxyglucose (FDG), PET/CT uses the enhanced glycolysis in malignant cells to visualize potential pathological foci within the body. However, several studies have failed to demonstrate superiority of FDG-PET/CT in the diagnostic work-up of primary breast cancer or in the evaluation of axillary nodal disease in newly diagnosed breast cancer [4] [5] [6] .
In contrast, for initial and recurrent breast cancer staging, PET/CT or PET alone has in many studies been demonstrated to be more accurate than conventional imaging methods [4, 5, [7] [8] [9] [10] in detecting extra-axillary nodal involvement and distant metastases.
Thus, in a prospective study of 60 patients with large (>3 cm) primary breast tumors, it was shown that PET/CT changed the initial staging in 42% of patients, but so far other studies published have been retrospective or have evaluated a heterogeneous patient population [5] . Therefore, the role of PET/CT in the initial staging of breast cancer remains unclear.
The purpose of the present study was to prospectively assess the clinical impact of preoperative PET/CT in the initial staging of newly diagnosed early breast cancer and to evaluate the potential role of PET/CT in future management of breast cancer patients.
materials and methods patients
From January 2008 to July 2010, 103 consecutive patients admitted to the Copenhagen University Hospital, Rigshospitalet, with newly diagnosed breast cancer and scheduled for surgery were included in this prospective study. All patients had a PET/CT scan carried out within 2 weeks before surgery. No patient received anticancer therapy before PET/CT or surgery and patients were to have a clinically assessed operable tumor ≥2 cm with no clinical suspicion of bilateral cancer, metastases or N3c disease at the time of diagnosis. Patients with inflammatory breast cancer, pregnant or lactating women as well as patients suffering from diabetes, claustrophobia or severe obesity (>140 kg, due to limitations of scanner aperture) were excluded.
Patients having contraindications for the use of i.v. contrast ( prior contrast reaction or impaired renal function) were also excluded.
The surgeons were blinded to the result of the PET/CT. The diagnosis of invasive breast cancer was confirmed by core biopsy in all patients and the stage of cancer was assessed by physical examination, mammography, US of the chest wall and axilla, chest X-ray and blood parameters.
The regional ethics committee approved the study protocol (ref. no. H-B-2007-056) and the study was conducted according to the Helsinki declaration. All study participants provided written informed consent before inclusion.
PET/CT imaging
All PET/CT scans were carried out using a GE Discovery LS PET/CT scanner (GE Medical Systems, Milwaukee, WI). Patients fasted for at least 6 h before i.v. injection of 400 MBq FDG in the antecubital vein contralateral to the breast cancer. Thirty minutes before PET acquisition, patients were asked to drink oral contrast media (500 ml, Ioxitalamat 12.6 mg I/ml; Pharmacy of Rigshospitalet, Copenhagen, Denmark), and immediately before PET acquisition, asked to void. The examination was carried out 60 min after the administration of FDG with the patient positioned supine with the arms raised above their head.
All CT images were obtained from the PET/CT scans and acquired immediately before PET performance with the multidetector four-slice spiral CT scanner and acquired as contrast-enhanced CT scans. With a pre-scan start delay of 40 s, i.v. contrast media (100 ml Ultravist® 300 mg I/ ml; Schering, Berlin, Germany) was injected with an automatic injection system (Medrad Envision CT Injector; Medrad Inc., Pittsburgh, PA) with a flow rate of 2.5 ml/min. The CT scan was carried out with a rotation time of 0.5 s, speed 15.0 mm per rotation, helical thickness 5 mm, pitch 1.5:1, 140 kV and 90-120 mA, depending on the size of the patient.
The PET scan followed immediately with an acquisition time of 3 min per bed position. Whole-body PET scanning consisted of imaging from the mid-thigh to the scalp using five to eight axial Fields of View with coverage of 14 cm.
The CT data were used for attenuation correction of the PET data. Both image sets were reconstructed in transaxial, coronal and sagittal images with a slice thickness of 5 mm. A nuclear medicine physician and a radiologist in collaboration interpreted the PET and the fused PET/CT images on the GE eNTEGRA PET workstation (GE, Milwaukee, Wisconsin, WI). CT images were reviewed at a picture archiving and communication system (PACS)-workstation (AGFA Impax 4.1, Mortsel, Belgium).
The effective radiation dose for the PET/CT scan was ∼18 mSv with 8 mSv from the FDG dose and 10 mSv from the CT scan [11] .
image interpretation
The PET/CT images were analyzed visually. For each study, a region of interest was drawn manually around the entire primary tumor. The maximum standardized uptake value (SUVmax) from the tumor was used original articles Annals of Oncology for further analysis. SUV is a semiquantitative analysis of radiotracer uptake and is defined as the ratio of radiotracer activity per milliliter of tissue to the activity in the injected dose corrected for decay and the patient's body weight [12] . Except for the primary tumor site, all foci with pathologic FDG uptake higher than liver activity were reported as positive and suspicious for malignancy if the uptake was focal and related to anatomical structures or pathological findings on the corresponding CT slices. More diffuse pathological uptake was reported as nonmalignant inflammatory changes and therefore reported as negative. Occasionally, some well known artifactual hot spots were seen (e.g. due too i.v. contrast during the CT acquisition) but did not lead to false-positive findings.
standard of reference
Distant metastases/new primary cancers were confirmed histologically by biopsy. Where biopsy was not possible or feasible, follow-up PET/CT or other imaging modalities was used as reference.
histological work-up of lymph nodes
Two serial frozen sections of 4 μm each were made of each sentinel lymph node and stained for hematoxylin and eosin (H&E) to search for possible metastases perioperatively. The frozen material was afterward thawed to −20°C and fixed in cold formalin ( + 5°C) and embedded in paraffin. The formalin-fixed paraffin-embedded lymph nodes were cut serially in 4-μm slides and stained for H&E, CK7 and CK-aecam, in two series with 250-μm distance in between series.
Before immunohistochemical (IHC) analyses, antigens were deparaffinized and retrieved with Dako Target Retrieval Solutions High pH for 20 min at 97°C (Code K 8002) using the Dako pretreatment link. After blocking endogenous peroxidase activity with Dako EnVision Flex + (Dako K 8002) for 5 min, tissue sections were incubated with IHC primary antibody, diluted in Dako antibody diluent (Dako K 8006) for 20 minutes at room temperature. The reaction was visualized by using Dako EnVisionFlex + mouse link for 15 min followed by Dako EnVision Flex + /HRP for 20 min and finally Dako EnVision Flex + diaminobenzidine for 10 min. The sections were counterstained with hematoxylin for 4 min. The IHC antibodies that were used are CK7, clone OV-TL 12/30, Dako M7018, diluted 1:400, CK-aecam: clone ae1/ae3 + 5dt (Biocare CM0162, diluted 1:400).
statistical methods
Sensitivity and specificity were calculated using standard methods. Sensitivity and specificity measures the proportion of correctly identified positives and negatives, respectively. results A total of 103 consecutive patients with newly diagnosed breast cancer were included in this study. Patient and tumor characteristics for patients with and without a change in stage/ treatment are listed in Table 1 . PET/CT identified the primary tumor in 100/103 patients with a sensitivity of 97%. The three PET-negative tumors were either invasive ductal (n = 2, size: 10 and 22 mm) or invasive lobular carcinoma (n = 1, size: 25 mm).
Thirty patients had a sentinel node biopsy (SNB) carried out only, whereas 73 patients underwent axillary lymph node dissection (ALND) including 36 patients who underwent both SNB and ALND (Table 1) . Axillary lymphadenectomy revealed axillary lymph node metastases in 71 patients (69%), including 7 patients with micrometastases only.
PET/CT detected 45/64 patients with axillary lymph node metastases (45/71 including micrometastases) and one case with axillary FDG uptake was considered a false-positive PET/ CT, as no malignancy was detected on pathological examination. Thus, on a patient-by-patient basis, PET/CT had a sensitivity of 63% and specificity of 97% for axillary lymph node detection. PET/CT did not detect any lymph node micrometastases and no axillary lymph node metastases were detected by PET/CT only.
Extra-axillary lymph node involvement was diagnosed in 12 patients by PET/CT in the internal mammary chain (IMC) (n = 10) and supraclavicular region (n = 2).
PET/CT detected 11 sites of distant malignancy in eight patients (8%), comprising bone (n = 5), ovary (n = 2), lung (n = 2), uterus (n = 1) and bone marrow (n = 1) metastases (Figure 1 and supplemental Table S1 , available at Annals of Oncology online). Histological biopsies revealed 2 of the 11 cases of distant malignancy to be new primary cancers. One case was a pulmonary cancer (adenocarcinoma, stage Ib) and in the second case, pathological revision could not distinguish whether the patient had two new primary tumors (ovary and endometrial), or a primary ovarian cancer with dissemination to the uterus, but deemed it more likely to be the former.
Six patients had distant metastases confirmed by either biopsy or other imaging modalities (supplemental Table S1 , available at Annals of Oncology online).
In total, 23 sites of extra-axillary malignancy in 15 patients were detected by PET/CT only (Table 2) , leading to an upgrade of initial staging in 14% (14/103) of patients and ultimately a modification of planned treatment in 8 (8%) patients (Table 2) .
Axillary lymph node metastases were observed in 13/15 (87%) patients who had a change in treatment or stage, and in 13/71 (18%) patients with axillary nodal disease, the stage and/ or treatment was changed (Table 1) .
Six patients (6%) had nonmalignant focal uptake of FDG ( Figure 2 ) confirmed with histological biopsies (n = 5) or US (n = 1) (supplemental Table S2 , available at Annals of Oncology online).
discussion
The purpose of this study was to prospectively assess the impact of preoperative PET/CT in the initial staging of cT2-3 breast cancer. To our knowledge, this is, to date, the largest prospective study of this kind, adding valuable information to the clinical presentation of breast cancer in newly diagnosed operable patients, as well as the utility and feasibility of PET/ CT in the initial staging.
In our study, PET/CT detected 23 sites of extra-axillary malignancy in 15 patients (15%), which led to a change in initial staging in 14 patients (14%) and subsequently to a modification of treatment plans in 8 patients (8%). In previous studies, PET/CT led to a change in stage in up to 42% of cases, resulting in a change of patient management in 13%-32% of cases [5, 8, 13, 14] . In studies with a 42% change of stage, a substantial part of the changes were due to axillary lymph node metastases detected by PET/CT only [5, 8, 13] , which Annals of Oncology original articles accounts for the large difference in patients with a change of stage as no axillary lymph node metastases were detected by PET/CT only in this study. No real standard of the initial staging procedure exists, and the use of more elaborate conventional staging methods, e.g. liver US, bone scan and CT of chest and/or abdomen-which is standard at other oncologic centers-could have lead to different results. For instance, it remains unclear whether bone scans would have detected the bone metastases that were detected by PET/CT in the present study and whether the schwannoma (supplemental Table S2 , available at Annals of Oncology online, and Figure 2 ) would have been false positive on a chest CT as well.
Reasons for the relative lower frequency of change of treatment in this study could be differences in selection of patients. Several earlier studies included more high-risk and heterogeneous populations [5, 8, 13, 14] .
Other reasons could be differences in standard therapy. At our institution, the IMC is automatically included in the field of radiation, if an indication of postoperative axilla irradiation exists. Radiation of the left IMC is conducted by use of gating. Thus, in contrast to most other studies [8, 13, 14] , diagnosis of IMC metastases did not change treatment strategy in any patient in the present study. Although metastases to the IMC has been reported to occur in 8%-10% of patients without axillary nodal involvement [15, 16] , all patients in the present study with IMC metastases had concomitant axillary lymph node metastases. Although IMC metastases indicate worse prognosis [17] , the clinical importance of IMC metastasis remains controversial and trials addressing surgical treatment or irradiation of IMC metastasis have either failed to demonstrate a survival benefit or yet to report mature data [15] . However, it has previously been suggested that metastases to the IMC might be associated with a twofold risk of relapse and breast cancer death [18] , which might indicate a potential impact for PET/CT on adequate therapy.
One patient (No. 7; Table 2 ) with IMC metastasis had axillary lymph node micrometastasis only but did not receive adjuvant radiation, as disseminated disease was diagnosed.
In six cases (6%), a nonmalignant focal uptake of FDG was confirmed with biopsy or US and considered as a false-positive result for PET/CT (supplemental Table S2 , available at Annals of Oncology online). False-positive findings require supplementary diagnostic procedures and may induce unnecessary psychological distress.
Strategies for treatment of axillary lymph nodes in earlystage breast cancer usually include SNB followed, in case of malignant involvement of the sentinel node, by ALND. 
original articles Annals of Oncology
In our study, PET/CT had a sensitivity of 63% for detection of axillary lymph node metastases and adds further evidence to the notion that PET/CT is probably inferior to SNB in evaluation of axillary lymph node involvement. This is in accordance with previous studies [19, 20] . However, with a specificity of 97% in detecting axillary lymph node metastases, PET/CT could potentially select patients for direct ALND and exempt the use of SNB in patients with axillary node-positive PET/CT. In a previous study, patients were selected based on their PET/CT axillary status to either ALND (PET/CT N + ) or SNB (PET/CT N0) and with a specificity of 100% for detection of axillary lymph node metastases spared 27 (20%) patients an unnecessary SNB [21] . In our study, with a 97% specificity, 45 (44%) patients could have been spared an SNB and proceeded directly to ALND. Recently, a systematic review and metaanalysis concluded against this approach as too many patients would undergo unnecessary ALND due to a high false-positive rate of PET/CT, and therefore PET/CT could not be recommended in the routine evaluation of axillary disease in early breast cancer [22] . We could not confirm this, as only one patient in the present study had a false-positive axillary PET/CT and would have undergone an unnecessary ALND if this approach would have been used. As false-negative SNB, defined as an axillary node-positive case with a negative SNB, has been reported in recent studies to occur in 5.5%-16.7% of cases [16] , a positive axillary PET/CT might enhance the accuracy of SNB and decrease the risk of a false-negative SNB. Further prospective investigations addressing this issue are needed.
The incidental detection of coexisting primary tumors has been reported in previous PET/CT studies [8, 21, 23] and it is well established that cancer patients have a higher risk and higher incidence of new primary tumors [24] . From the two examples in our study, it is plausible that the early detection of the new primary cancer is beneficial to patients and not only results in lead time bias. Patient 4 (primary lung cancer) received primary pulmonary surgery with no adjuvant treatment and is still recurrence free >25 months after diagnosis whereas patient 2 (endometrial/ovary cancer) received both primary surgery (oopho-hysterectomy) and adjuvant chemotherapy and is also recurrence free >27 months after diagnosis. In our study, a significant proportion of patients were found to have extra-axillary malignancy that subsequently led to modification of treatment. Among patients with N-negative disease, 6% had a change in initial disease stage compared with 18% of N-positive patients. Future studies addressing this group separately are warranted. Whether or not a change in disease stage or treatment at initial assessment leads to a survival benefit is unknown and also requires further investigations.
In conclusion, in this study, we found that PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. In the initial stage assessment, preoperative FDG-PET/ CT has a substantial impact on staging and on clinical management and we suggest that PET/CT could be considered in the initial assessment of patients with newly diagnosed node-positive early-stage breast cancer ≥2 cm. 
